This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2007 by Tel-Aviv Sourasky Medical Center.
Recruitment status was:  Not yet recruiting
Information provided by:
Tel-Aviv Sourasky Medical Center Identifier:
First received: August 15, 2007
Last updated: NA
Last verified: August 2007
History: No changes posted

A relationship between IBD and spondyloarthropathy is well recognized. ASCA ( anti saccharomyces cerevisiae antibodies)are considered to be a serological marker for Crohn's disease and have been studied in patients with spondyloarthropathy with conflicting results. More recently, new serological markers for IBD have been described. These markers are antibodies to certain defined glycans , and their use may permit an improved diagnosis of IBD.

The aim of our study is to investigate wether these new serological markers are present in the sera of patients with spondyloarthropathy.

Psoriatic Arthritis Ankylosing Spondylitis Undifferentiated Spondyloarthropathy

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Tel-Aviv Sourasky Medical Center:

Study Start Date: September 2007

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • diagnosis of psoriatic arthritis, ankylosing spondylitis, or undifferentiated spondyloarthropathy

Exclusion Criteria:

  • diagnosed inflammatory bowel disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00517101

Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
Principal Investigator: valerie aloush, MD Tel-Aviv Sourasky Medical Center
  More Information Identifier: NCT00517101     History of Changes
Other Study ID Numbers: TAMSC-07-VA-318-CTIL
Study First Received: August 15, 2007
Last Updated: August 15, 2007

Keywords provided by Tel-Aviv Sourasky Medical Center:
inflammatory bowel disease

Additional relevant MeSH terms:
Spondylitis, Ankylosing
Arthritis, Psoriatic
Bone Diseases, Infectious
Bone Diseases
Musculoskeletal Diseases
Spinal Diseases
Joint Diseases
Skin Diseases, Papulosquamous
Skin Diseases
Immunologic Factors
Physiological Effects of Drugs processed this record on September 25, 2017